Dr. Soga, Senior Vice President of United Immunity, will present research results of UI-101 at the upcoming Annual Meeting of Society for Immunotherapy of Cancer (SITC) in San Diego, USA on November 3-5.
The title is “UI-101, a TLR7/8 agonist encapsulated in cholesteryl pullulan nanoparticle targeting tumor-associated macrophages via binding to DC-SIGN, elicits potent anti-tumor immunity without severe side effect.”